| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/24/2000 | EP1001933A1 Caspases and apoptosis |
| 05/24/2000 | EP1001932A1 Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor |
| 05/24/2000 | EP1001930A2 N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases |
| 05/24/2000 | EP1001927A2 Novel polyamine analogues as therapeutic and diagnostic agents |
| 05/24/2000 | EP1001814A1 Controlled release microencapsulated ngf formulation |
| 05/24/2000 | EP1001810A1 Pharmaceutical composition with neurotrophic-like biological activity |
| 05/24/2000 | EP1001807A1 Adoptive immunotherapy utilizing heat shock/stress protein-peptide complexes for prevention/treatment of cancer or infectious diseases |
| 05/24/2000 | EP1001801A1 Product comprising at least a double stranded rna combined with at least an antiviral agent |
| 05/24/2000 | EP1001796A1 Antacid and papain combination |
| 05/24/2000 | EP1001785A1 Use of colchinol derivatives as vascular damaging agents |
| 05/24/2000 | EP1001774A1 Use of phospholamban inhibitors to increasing coronary flow |
| 05/24/2000 | EP1001766A1 Compounds and methods |
| 05/24/2000 | EP1001765A1 Internal two photon excitation device for delivery of pdt to diffuse abnormal cells |
| 05/24/2000 | EP1001764A1 Heterocyclic amide compounds as cell adhesion inhibitors |
| 05/24/2000 | EP1001762A1 Method of using neurotrophic carbamates and ureas |
| 05/24/2000 | EP1001756A1 Synergistically acting compositions for selectively combating tumor tissue |
| 05/24/2000 | EP1001755A2 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| 05/24/2000 | EP1001753A1 Low dosed 15-desoxyspergualine preparations |
| 05/24/2000 | EP1001752A1 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| 05/24/2000 | EP1001741A1 Use of amino phenol amide derivatives as depigmentation agents |
| 05/24/2000 | EP1001685A1 Nutritional composition containing methionine |
| 05/24/2000 | EP0821590A4 Large area submucosal graft constructs and method for making the same |
| 05/24/2000 | EP0817767B1 Bicyclic amine derivatives and their use as anti-psychotic agents |
| 05/24/2000 | EP0799238B1 14alpha,17alpha-c2-bridged 19-nor-progesterone derivatives |
| 05/24/2000 | EP0793674B1 Human neutrophil elastase inhibitors |
| 05/24/2000 | EP0787135B1 Water-soluble epipodophyllotoxin derivatives, preparation method therefor, and use thereof as a drug and for treating cancer |
| 05/24/2000 | EP0720620B1 Glutathione analogs and paralog panels comprising glutathione mimics |
| 05/24/2000 | EP0687270B1 Osteogenic growth oligopeptides and pharmaceutical compositions containing them |
| 05/24/2000 | EP0626969B1 CoA-IT AND PAF INHIBITORS |
| 05/24/2000 | CN1254376A 端粒酶逆转录酶 Telomerase reverse transcriptase |
| 05/24/2000 | CN1254375A Motilin homologs |
| 05/24/2000 | CN1254374A Inhibitors of cellulolytic, xylanolytic and 'beta'-glucanolytic enzymes |
| 05/24/2000 | CN1254347A Analogs of parathyroid hormone |
| 05/24/2000 | CN1254345A Serine protease inhibitors |
| 05/24/2000 | CN1254344A Estrogenic 10-Noradnrost-17-one derivatives with aromatic B-ring |
| 05/24/2000 | CN1254342A Pharmaceutically acceptable salts of 5 alpha-pregnan-3-beta, 16 alpha-diol-20-one 3-sulfate useful as progestins and CNS disorders |
| 05/24/2000 | CN1254341A Pharmaceutically accpetable salts of 3-hydroxy-estr-5-(10)-en-17-one 3-sulphate active as estrogens |
| 05/24/2000 | CN1254337A N-hydroxy 4-sulfonyl butyramide compounds |
| 05/24/2000 | CN1254335A Nicotinamide derivatives |
| 05/24/2000 | CN1254333A Immunotherapeutic imides/amides |
| 05/24/2000 | CN1254293A Targeted therapeutic delivery of vitamin D compounds |
| 05/24/2000 | CN1254290A Genes coding proteins for early liver development and their use in diagnosing and treating liver disease |
| 05/24/2000 | CN1254284A Activated protein C formulations |
| 05/24/2000 | CN1253948A Substituted tricyclic compound |
| 05/24/2000 | CN1253833A Cell adhesion molecule expression inhibitor |
| 05/24/2000 | CN1253824A Chinese medicine preparation for curing hyperplasia of mamary glands and its preparation method |
| 05/24/2000 | CN1253804A Body-building medicated pillow |
| 05/24/2000 | CN1253783A Kidney-supplementing yang-invigorating channels-freeing dampness-dispelling medicated liquor |
| 05/24/2000 | CN1052731C Compounds with growth hormone releasing properties |
| 05/24/2000 | CN1052730C Compounds with growth hormone releasing properties |
| 05/24/2000 | CN1052729C Steroids containing in position 20 aminosubstituted chain, their preparation process and use, and pharmaceutical compositions containing them |
| 05/24/2000 | CN1052723C Bicyclic aromatic compounds as therapeutic agents, its preparing method and drug composition containing said compound |
| 05/24/2000 | CN1052654C Anti-senility preparation and preparing method thereof |
| 05/24/2000 | CN1052643C Method for preparing refined male silk moth powder |
| 05/23/2000 | US6066739 Process for producing optically active imidazole compounds, intermediates for synthesizing the same, and process for producing the same |
| 05/23/2000 | US6066738 Inhibitors of farnesyl-protein transferase |
| 05/23/2000 | US6066730 Boronic ester and acid compounds, synthesis and uses |
| 05/23/2000 | US6066722 Nucleoside analogues used as antiprotozoal agents especially against plasmodium |
| 05/23/2000 | US6066717 RsbW-1 protein |
| 05/23/2000 | US6066673 Enzyme inhibitors |
| 05/23/2000 | US6066668 Formulations and methods of reducing toxicity of antineoplastic agents |
| 05/23/2000 | US6066663 Oxidation derivatives of indolylalkylamines and their use as drugs |
| 05/23/2000 | US6066662 Use in control or prevention of rheumatoid arthritis and osteoarthritis or in the treatment of invasive tumours, atherosclerosis or multiple sclerosis |
| 05/23/2000 | US6066657 For the treatment of disease states associated with proteins which mediate cellular activity, for example by inhibiting tumor necrosis factor or phosphodiesterase iv |
| 05/23/2000 | US6066650 Inhibitors of microsomal triglyceride transfer protein and method |
| 05/23/2000 | US6066645 Administering an effective amount of the protective agent to a patient receiving one or more antineoplastic agents; compounds useful as protective agents have either a sulfhydryl moiety or are reducible disulfides |
| 05/23/2000 | US6066644 Treatment of various cns disorders |
| 05/23/2000 | US6066643 Administering to said mammal an effective amount of moxonidine, or a pharmaceutically acceptable salt thereof |
| 05/23/2000 | US6066642 For selectively blocking the a3 adenosine receptor of a mammal |
| 05/23/2000 | US6066641 Phosphodiesterases as molecular targets for anti-asthmatic agents |
| 05/23/2000 | US6066633 Prevent tissue degradation |
| 05/23/2000 | US6066626 Supplying active human galactosidase to cells |
| 05/23/2000 | US6066621 Response inhibiting peptide |
| 05/23/2000 | US6066617 Polypeptide |
| 05/23/2000 | US6066447 Including nucleoside dimers with modified backbones; for viricides and antisense agents |
| 05/23/2000 | US6066321 Diagnosing inflammation and autoimmune diseases |
| 05/23/2000 | US6066319 Administering membrane attack complex (mac) transmembrane channel forming agent which is an antibody simultaneously therewith an effective amount of a therapeutic or diagnostic agent |
| 05/23/2000 | CA2200959C 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives |
| 05/23/2000 | CA2171637C Substituted azaheterocyclecarboxylic acids |
| 05/18/2000 | WO2000028062A1 Novel system for regulating transgene expression |
| 05/18/2000 | WO2000028061A2 Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| 05/18/2000 | WO2000028045A2 Human hydrolase proteins |
| 05/18/2000 | WO2000028034A2 Cytokine signal regulators |
| 05/18/2000 | WO2000028022A1 Pge synthase and methods and means for modulating its activity |
| 05/18/2000 | WO2000028020A2 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor |
| 05/18/2000 | WO2000028019A2 Antisense oligomer |
| 05/18/2000 | WO2000028010A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |
| 05/18/2000 | WO2000027998A2 Method and compositions for improving allogeneic hematopoietic cell transplantation |
| 05/18/2000 | WO2000027879A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 05/18/2000 | WO2000027874A2 Nucleic acids encoding transferrin receptor-like proteins and products related thereto |
| 05/18/2000 | WO2000027868A2 Connective tissue growth factor (ctgf) and methods of use |
| 05/18/2000 | WO2000027866A1 Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof |
| 05/18/2000 | WO2000027850A2 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | WO2000027848A1 Pyrazolopyrimidinone derivatives for the treatment of impotence |
| 05/18/2000 | WO2000027842A1 Compounds |
| 05/18/2000 | WO2000027832A2 Thiazole derivatives as ppar gamma ligands |
| 05/18/2000 | WO2000027822A2 Tricyclic pyrazole derivatives |
| 05/18/2000 | WO2000027820A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors |
| 05/18/2000 | WO2000027819A2 Antrhranilic acid amides and the use thereof as medicaments |
| 05/18/2000 | WO2000027815A2 N-substituted azacycles, their preparation and their use as orl-1 receptor ligands |